Nombre: José Carlos Menéndez Ramos

Email: josecm@ucm.es

Teléfono de contacto: (+34)913941840

Posición y cargo: Catedrático de Universidad. Director de la Unidad de Microanálisis Elemental, Universidad Complutense. Coordinador del Máster Oficial en Descubrimiento de Fármacos. Coordinador en la UCM del programa de doctorado en Química Médica.

Grupo de Investigación: Heterociclos de interés biológico y terapéutico (BIOHET), director.

Docencia: Grado en Farmacia. Máster en Descubrimiento de Fármacos (interuniversitario). Doctorado en Química Médica (interuniversitario).

Área de Conocimiento: Química Orgánica

Google Scholar: MROIO74AAAAJ. **SCOPUS:** 6506907063. **ORCID:** 0000-0002-0560-8416. **Researcher ID**: B-7529-2014

Web: https://www.researchgate.net/profile/J_Carlos_Menendez

Biography: José Carlos Menéndez obtained degrees in Pharmacy (UCM) and Chemistry (UNED) and a PhD in Pharmacy in 1988, under the supervision of Dr. Mónica M. Söllhuber. Following a postdoctoral placement at the Department of Chemistry at Imperial College, London, under the supervision of Prof. Steven V. Ley (1988-89), he obtained a permanent position at the Department of Organic and Medicinal Chemistry at the School of Pharmacy, Universidad Complutense, where he has pursued his whole career and is presently a Full Professor. He has also been a Visiting Professor at the Universities Paul Cezanne - Aix-Marseille III (France, 2007), Madurai Kamaraj (India, 2013) and Bologna (Italy, 2014). He has co-authored about 300 publications and patents in several areas of synthetic and medicinal chemistry, with a Hirsch index of 41. He is a member of the Spanish Royal Academy of Pharmacy (medal 15).

Research Interests:

- New multitarget-directed ligands for the treatment of neurodegenerative diseases.

- New small-molecule theranostic compounds for the diagnosis and treatment of neurodegenerative diseases.

- Diversity-oriented synthesis and its application to the discovery of bioactive compounds.

- Development of new multicomponent and domino reactions.

- New chemotherapeutic agents against cancer and neglected infectious diseases.